First precision cell therapy targeting dry mouth as seen in Sjögren’s disease and graft-versus-host disease.
Today, we are announcing that the University of Wisconsin-Madison School of Medicine and Public Health in partnership with the UW Carbone Cancer Center received clearance from the U.S Food and Drug Administration (FDA) for an investigational New Drug (IND) application for autologous bone-marrow derived mesenchymal stromal cells to treat medical xerostomia.
This unique UW Program for Advanced Cell Therapy PACT-sponsored first-in-human study will be led at UW by Dr. Sara McCoy, an internationally recognized expert in Sjögren’s disease who runs one of the major national Sjögren’s clinics at UW Health.